| 摘要: |
| ［摘要］ 布鲁顿酪氨酸激酶（BTK）抑制剂通过靶向抑制B细胞受体通路中的BTK阻碍B细胞相关恶性肿瘤的生长，但部分患者出现与药物相关的心房颤动（AF）。AF作为最常见的心律失常类型之一，研究其发生发展的机制在心脏相关疾病的治疗中十分重要。该文就BTK抑制剂诱导AF发生的机制研究进展作一综述。 |
| 关键词: 布鲁顿酪氨酸激酶抑制剂 心房颤动 发病机制 |
| DOI：10.3969/j.issn.1674-3806.2023.02.20 |
| 分类号:R 541 |
| 基金项目:国家自然科学基金项目（编号：82160056，81960050）；贵州省科技计划项目（黔科合基础［2020］1Y293）；贵州省卫生健康委员会科学技术基金项目（编号：gzwkj2021-193） |
|
| Progress in mechanisms of Bruton′s tyrosine kinase inhibitor-induced atrial fibrillation |
|
GAO Shi-hao, ZHOU Tao
|
|
Zunyi Medical University, Guizhou 563000, China
|
| Abstract: |
| ［Abstract］ Bruton′s tyrosine kinase(BTK) inhibitors can inhibit the growth of B cell-related malignancies by targeting BTK in the B cell receptor pathway. However, during the use of BTK inhibitors, some patients develop drug-related atrial fibrillation(AF). AF is one of the most common types of arrhythmia, and it is very important to study the mechanisms of its occurrence and development in the treatment of heart-related diseases. This paper reviews the progress in mechanisms of BTK inhibitor-induced AF. |
| Key words: Bruton′s tyrosine kinase inhibitor Atrial fibrillation(AF) Pathogenesis |
